Lexicon Pharmaceuticals, Inc.
网页Therapeutic Areas. Through our unique approach to gene science based on Nobel Prize-winning technology, we are moving forward rapidly to bring innovative therapies to …
Innovative Pipeline | Lexicon Pharmaceuticals
网页Innovative Pipeline. We are commercializing INPEFA ® (sotagliflozin) for the treatment of heart failure. We have also advanced multiple other drug candidates into late-stage …
U.S. FDA approves Lexicon Pharma's drug for heart …
网页2023年5月26日 · The U.S. Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals Inc's drug for a broad treatment of heart failure, including in adult patients with type 2 diabetes, the company...
Lexicon Pharmaceuticals, Inc.
网页Lexicon Pharmaceuticals is a biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and …
Lexicon Pharmaceuticals Provides Business and Pipeline Update at …
网页2024年1月8日 · Lexicon Pharmaceuticals, Inc. -INPEFA® Launch Positioned for Acceleration in 2024-. -Clinical Data and FDA Feedback Support INPEFA Life Cycle …
Lexicon Pharmaceuticals | Wikipedia
网页Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology. The company's clinical …
Lexicon Pharmaceuticals Highlights Oral Presentation of
网页2022年11月8日 · Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain and identified LX9211 and another …
Lexicon’s LX9211 Shows Significant and Consistent Benefits
网页2022年11月14日 · Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain and identified LX9211 and another …
Lexicon Pharmaceuticals Highlights Oral Presentation of Final …
网页2022年11月8日 · Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain and identified LX9211 and another …
Lexicon Pharmaceuticals, Inc. | LinkedIn
网页We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has ...
跳至内容